What is Glutathione? The Cell’s Master Antioxidant Explained
A research guide to glutathione (GSH) — the cysteine-containing tripeptide at the centre of cellular redox balance, detoxification chemistry and ferroptosis research.
Glutathione is a tripeptide built from glutamate, cysteine and glycine (γ-L-glutamyl-L-cysteinylglycine). In its reduced form (GSH) it is the most abundant low-molecular-weight thiol in mammalian cells, typically present at millimolar concentrations. The balance between reduced glutathione and its oxidised disulfide form (GSSG) is one of the most widely used read-outs of cellular redox status. Because it sits where antioxidant defence, xenobiotic metabolism and regulated cell death meet, glutathione is one of the most frequently measured — and deliberately manipulated — molecules in redox biology research.
What Makes Glutathione Unusual?
Most peptides are linked through the α-carboxyl group of each amino acid. Glutathione is not: its glutamate is joined to cysteine through the side-chain γ-carboxyl group. This γ-glutamyl bond protects the molecule from most intracellular peptidases, so glutathione can build up to high concentrations inside cells. It is broken down mainly outside the cell by the membrane enzyme γ-glutamyl transferase (GGT), which releases its amino acids for re-uptake and re-synthesis.
The reactive part of the molecule is the thiol (–SH) group of cysteine. It donates electrons to neutralise reactive species and forms reversible disulfide bonds, which is why glutathione can act as an antioxidant, an enzyme co-substrate and a redox signalling molecule all at once.
Biosynthesis and Recycling
Cells make glutathione in two ATP-dependent steps:
- Glutamate–cysteine ligase (GCL): joins glutamate and cysteine to form γ-glutamylcysteine. This is the rate-limiting step, and it is feedback-inhibited by GSH itself.
- Glutathione synthetase (GS): adds glycine to complete the tripeptide.
Cysteine supply usually limits how fast glutathione can be made, which is why cysteine donors such as N-acetylcysteine (NAC) — often combined with glycine — are studied as indirect ways of raising glutathione. Once oxidised to GSSG, glutathione is recycled back to GSH by glutathione reductase, using NADPH as the electron donor. This links glutathione status directly to the pentose phosphate pathway and the cell’s NADPH supply.
Mechanism of Action
- Peroxide detoxification: Glutathione peroxidases use GSH to reduce hydrogen peroxide and lipid hydroperoxides to water and alcohols, producing GSSG in the process.
- Ferroptosis control: The selenoenzyme GPX4 uses GSH to repair oxidised membrane phospholipids. When GSH runs out or GPX4 is blocked, iron-dependent lipid peroxidation drives a regulated form of cell death called ferroptosis.
- Conjugation chemistry: Glutathione S-transferases attach GSH to electrophilic drugs, toxins and reactive metabolites — the first step towards their excretion as mercapturic acids.
- Redox signalling: Reversible S-glutathionylation of protein cysteine residues shields them from irreversible oxidation and modulates enzyme and transcription-factor activity.
- Cysteine reservoir: Glutathione is a stable storage and transport form of cysteine, which is otherwise readily oxidised.
Key Research Areas
Oxidative Stress and Redox Biology: The GSH/GSSG ratio is a standard marker in cell-culture and animal models of oxidative stress, mitochondrial dysfunction and inflammation.
Ferroptosis and Cancer Biology: Depleting glutathione — for example by blocking cystine import or GSH synthesis — is a core tool for inducing and studying ferroptosis, an active area of cancer and neurodegeneration research.
Ageing: Studies report lower glutathione synthesis in older adults, which has made glutathione and its precursors a recurring focus of ageing research.
Neurodegeneration: Glutathione is depleted early in the course of Parkinson’s disease, which prompted small clinical studies of intravenous and intranasal glutathione.
Pigmentation: Glutathione inhibits tyrosinase and shifts melanin production from darker eumelanin towards lighter phaeomelanin. This underlies its widespread — and largely unregulated — promotion as a “skin-lightening” agent.
Compound Profile
| Property | Detail |
|---|---|
| Sequence | γ-L-Glutamyl-L-cysteinylglycine (γ-Glu-Cys-Gly) |
| Forms | Reduced (GSH); oxidised disulfide (GSSG) |
| Molecular formula | C10H17N3O6S (GSH) |
| Molecular weight | 307.3 g/mol (GSH); 612.6 g/mol (GSSG) |
| CAS number | 70-18-8 (GSH); 27025-41-8 (GSSG) |
| Typical cellular level | Roughly 1–10 mM, almost entirely as GSH |
| Key enzymes | Glutamate–cysteine ligase, glutathione synthetase, glutathione reductase, glutathione peroxidases (including GPX4), glutathione S-transferases |
| Regulatory status | Sold as a food-supplement ingredient; injectable glutathione is not a licensed medicine in the UK |
Key Published Research
- Biosynthesis and protective roles (2009, 2013): Reviews set out glutathione’s two-step synthesis, its control by cysteine supply and GCL feedback, and its roles in antioxidant defence and detoxification.1,2
- Ferroptosis (2014): GPX4 was identified as the central regulator of ferroptotic cell death; depleting glutathione or inhibiting GPX4 triggered lethal lipid peroxidation in cancer cells.3
- Oral availability — single dose (1992): In seven healthy volunteers, a single 3 g oral dose did not significantly raise plasma glutathione, cysteine or glutamate over 270 minutes, which the authors put down to breakdown by intestinal and hepatic γ-glutamyl transferase.4
- Four-week trial (2011): In 40 healthy adults, 500 mg twice daily for four weeks did not change urinary oxidative stress markers or red-cell glutathione status compared with placebo.5
- Six-month trial (2015): In 54 adults, 250 or 1,000 mg/day raised glutathione stores in a dose- and time-dependent way — by 30–35% in red cells, plasma and lymphocytes and 260% in buccal cells at the higher dose — with levels returning to baseline after a one-month washout.6
- Liposomal form (2018): A one-month pilot in 12 adults reported increases of up to 40% in whole-blood glutathione alongside lower oxidative stress markers; the study was small, had no placebo group and was funded by the liposome supplier.7
- Precursor approach (2011, 2023): Dietary cysteine and glycine restored glutathione synthesis in older adults, and a 16-week randomised trial of glycine plus NAC (GlyNAC) in 24 older adults reported improvements in glutathione, oxidative stress and physical-function measures versus placebo.8,9
- Pigmentation (2012, 2016, 2017): Oral glutathione 500 mg/day for four weeks lowered the melanin index at all six sites measured in 60 students, significantly at two of them; a 12-week trial of 250 mg/day GSH or GSSG reported trends towards a lower melanin index and fewer wrinkles at some sites. A 2016 review found no evidence that intravenous glutathione works for skin lightening.10–12
- Parkinson’s disease (2009, 2017): Intravenous glutathione (1,400 mg three times a week for four weeks, 21 patients) was well tolerated but did not significantly change symptom scores; a phase IIb trial of intranasal glutathione in 45 patients found no advantage over placebo.13,14
Regulatory & Safety Status (2026)
- August 2026 — FDA warning: The US FDA told compounders to stop using a lot of dietary-supplement-grade glutathione supplied by Medisca after at least 30 patients had fever, chills, signs of shock or sepsis-like reactions following intravenous glutathione — effects consistent with endotoxin contamination. Two Texas pharmacies recalled products (FDA notice). FDA had issued a similar warning in 2019, when its laboratory found excessive bacterial endotoxin in another supplier’s glutathione powder (FDA notice).
- UK — “skin-whitening” drips: Intravenous glutathione drips are not licensed medicines. In June 2025 the Chartered Trading Standards Institute warned that more than 300 salons were offering them (CTSI), and MHRA guidance quoted by the Joint Council for Cosmetic Practitioners states that cosmetic use is not an admissible “special need” for prescribing an unlicensed medicine (JCCP).
- Research-grade material: For cell-culture and in-vivo models, identity, purity and endotoxin content all matter. Supplement-grade material is not made to the standard needed for sterile laboratory work.
Handling in the Laboratory
Reduced glutathione oxidises readily in solution, so handling has a large effect on results:
- Solutions: Prepare fresh and keep cold. Autoxidation to GSSG is faster at neutral-to-alkaline pH and in the presence of trace metal ions; chelators such as EDTA, and degassed or mildly acidic buffers where the method allows, slow it down.
- Storage: Keep lyophilised powder sealed, dry and cold, protected from moisture and light.
- Measuring GSH and GSSG: Block free thiols (for example with N-ethylmaleimide) or acidify samples immediately after collection — otherwise GSH oxidises during processing and inflates the apparent GSSG. The enzymatic recycling (DTNB/glutathione reductase) assay and LC-MS are the standard methods.15
Evidence Quality & Limitations
Glutathione’s biochemistry is among the best characterised in cell biology. The human supplementation evidence is much thinner: trials are small, short and mixed, with single-dose and four-week studies showing no change and a six-month trial showing raised stores. Skin-lightening studies are small and short-term, there are no robust trials supporting intravenous use for cosmetic purposes, and clinical studies in Parkinson’s disease have not shown benefit over placebo. Findings from cell and animal models should not be assumed to carry over to humans.
References
- Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30:1–12. PubMed
- Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013;1830:3143–53. PubMed
- Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156:317–31. PubMed
- Witschi A, et al. The systemic availability of oral glutathione. Eur J Clin Pharmacol. 1992;43:667–9. PubMed
- Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17:827–33. PubMed
- Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54:251–63. PubMed
- Sinha R, et al. Oral supplementation with liposomal glutathione elevates body stores of glutathione and markers of immune function. Eur J Clin Nutr. 2018;72:105–11. PubMed
- Sekhar RV, et al. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. Am J Clin Nutr. 2011;94:847–53. PubMed
- Kumar P, et al. Supplementing glycine and N-acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. J Gerontol A Biol Sci Med Sci. 2023;78:75–89. PubMed
- Arjinpathana N, Asawanonda P. Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. J Dermatolog Treat. 2012;23:97–102. PubMed
- Weschawalit S, et al. Glutathione and its antiaging and antimelanogenic effects. Clin Cosmet Investig Dermatol. 2017;10:147–53. PubMed
- Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016;82:262–72. PubMed
- Hauser RA, et al. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009;24:979–83. PubMed
- Mischley LK, et al. Phase IIb study of intranasal glutathione in Parkinson’s disease. J Parkinsons Dis. 2017;7:289–99. PubMed
- Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2006;1:3159–65. PubMed

